Truist analyst Richard Newitter raised the firm’s price target on iRhythm (IRTC) to $175 from $160 and keeps a Buy rating on the shares after its Q2 earnings beat. The firm expect iRhythm to see strength following a notable $13M revenue beat fueled by core business strength, Zio AT adoption, and progress with innovative channel partners, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC: